Scarica l'app Stockscreener
21.17
1.63%
0.34
Dopo l'orario di chiusura:
21.17
Precedente Chiudi:
$20.83
Aprire:
$20.58
Volume 24 ore:
146.59K
Relative Volume:
0.76
Capitalizzazione di mercato:
$898.38M
Reddito:
-
Utile/perdita netta:
$-161.15M
Rapporto P/E:
-5.6987
EPS:
-3.7149
Flusso di cassa netto:
$-138.61M
1 W Prestazione:
+10.09%
1M Prestazione:
+20.28%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$20.31
$21.76
Intervallo di 1 settimana:
$17.96
$21.76
Portata 52W:
$12.24
$21.76
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Nome
Maplight Therapeutics Inc
Settore
Industria
Telefono
650-839-4360
Indirizzo
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
21.17 | 898.38M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-11-21 | Iniziato | Jefferies | Buy |
| 2025-11-21 | Iniziato | Leerink Partners | Outperform |
| 2025-11-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-21 | Iniziato | Stifel | Buy |
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
Maplight Therapeutics (NASDAQ:MPLT) Reaches New 52-Week HighHere's Why - MarketBeat
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
All News for MPLT : MapLight Therapeutics, Inc. - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Issues Quarterly Earnings Results, Misses Estimates By $1.42 EPS - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
MapLight Therapeutics Announces 2025 Financial Results, Advances Clinical Pipeline for Schizophrenia, Autism, and Alzheimer’s Trials - Minichart
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 5.6%What's Next? - MarketBeat
MapLight Therapeutics 2023 Annual Report: Innovative CNS Drug Discovery, Pipeline, and Risk Factors Overview - Minichart
MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position - TipRanks
Stifel reiterates Buy rating on MapLight Therapeutics stock By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on MapLight Therapeutics stock - Investing.com
MapLight Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MapLight Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
MapLight Therapeutics 10-K: Revenue $0, Net loss $161.2M - TradingView
[10-K] MapLight Therapeutics, Inc. Files Annual Report - Stock Titan
Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share - MarketScreener
MapLight Therapeutics (NASDAQ: MPLT) widens 2025 loss but funds runway through 2027 - Stock Titan
Two Phase 2 readouts ahead as MapLight says cash lasts through 2027 - Stock Titan
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - MarketScreener
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - MarketBeat
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - TipRanks
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Finviz
MPLT Earnings History & Surprises | EPS & Revenue Results | MAPLIGHT THERAPEUTICS INC (NASDAQ:MPLT) - ChartMill
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
MapLight2026 Funding Rounds & List of Investors - Tracxn
MapLight $251M IPO Defies Market Slowdown Amid Federal Shutdown - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
MapLight Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $186,301.84 in Stock - Defense World
MapLight Therapeutics Insiders Signal Confidence with Share Purchases () - aktiencheck.de
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Maplight Therapeutics Inc Azioni (MPLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):